Research programme: pain therapeutics - AxxamAlternative Names: BKR1 antagonist - Axxam; CB2 agonist - Axxam; Nav 1.7 blocker - Axxam; TRPM8 blocker - Axxam
Latest Information Update: 02 Feb 2011
At a glance
- Originator Axxam; Newron Pharmaceuticals; Primm srl; University of Milan Bicocca
- Developer Axxam; Newron Pharmaceuticals
- Mechanism of Action Bradykinin B1 receptor antagonists; Cannabinoid receptor CB2 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Purinergic P2X7 receptor antagonists; TRPM8 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Pain
Most Recent Events
- 02 Feb 2011 Early research is ongoing in Italy